Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 9.

Gautschi, Oliver; Rothschild, Sacha I; Li, Qiyu; Matter-Walstra, Klazien; Zippelius, Alfred; Betticher, Daniel C; Früh, Martin; Stahel, Rolf A; Cathomas, Richard; Rauch, Daniel; Pless, Miklos; Peters, Solange; Froesch, Patrizia; Zander, Thilo; Schneider, Martina; Biaggi, Christine; Mach, Nicolas; Ochsenbein, Adrian F; Swiss Group for Clinical Cancer Research (SAKK) (2017). Bevacizumab plus pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous non-small-cell lung cancer: Update from the swiss group for clinical cancer research (SAKK) 19/09 trial. Clinical Lung Cancer, 18(3):303-309.

Matter-Walstra, Klazien; Schwenkglenks, Matthias; Betticher, Daniel; von Moos, Roger; Dietrich, Daniel; Baertschi, Daniela; Koeberle, Dieter (2016). Bevacizumab continuation versus treatment holidays after first-line chemotherapy with bevacizumab in patients with metastatic colorectal cancer: a health economic analysis of a randomized phase 3 trial (SAKK 41/06). Clinical Colorectal Cancer, 15(4):314-320.

Matter-Walstra, Klazien; Schwenkglenks, Matthias; Aebi, Stefan; Dedes, Konstantin; Diebold, Joachim; Pietrini, Mario; Klingbiel, Dirk; von Moos, Roger; Gautschi, Oliver; Swiss Group for Clinical Cancer Research (SAKK) (2016). A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing. Journal of Thoracic Oncology, 11(11):1846-1855.

Matter-Walstra, Klazien; Ruhstaller, T; Klingbiel, D; Schwenkglenks, Matthias; Dedes, K J (2016). Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer Research and Treatment, 158(1):51-57.

Matter-Walstra, Klazien; Braun, R; Kolb, C; Ademi, Z; Dummer, R; Pestalozzi, B C; Schwenkglenks, Matthias (2016). Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors. British Journal of Dermatology, 174(2):463.

Schwenkglenks, Matthias; Matter-Walstra, Klazien (2016). Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments. Expert Review of Pharmacoeconomics & Outcomes Research, 16(2):207-219.

Matter-Walstra, Klazien; Klingbiel, Dirk; Szucs, Thomas; Pestalozzi, Bernhard C; Schwenkglenks, Matthias (2014). Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied? Pharmacoeconomics, 32(6):591-599.

Jakovljevic, Mihajlo; Gutzwiller, Florian; Schwenkglenks, Matthias; Milovanovic, Olivera; Rancic, Nemanja; Varjacic, Mirjana; Stojadinovic, Dobrivoje; Dagovic, Aleksandar; Matter-Walstra, Klazien (2014). Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 19(4):1111-1120.

Matter-Walstra, Klazien; Joerger, Markus; Kühnel, Ursula; Szucs, Thomas D; Pestalozzi, Bernhard; Schwenkglenks, Matthias (2012). Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value in Health, 15(1):65-71.

This list was generated on Sun Nov 18 15:18:06 2018 CET.